Ambrx | protein therapeutics - antibody drug conjugates

A Convergence of Chemistry And Biology To Create Better Medicine

Learn More

WHAT WE BELIEVE

Ambrx is developing innovative protein therapeutics that preserve potency, reduce dosing frequency and improve homogeneity of the drug substance.

Learn More

Our Technology

Ambrx is harnessing the power of an expanded genetic code to optimize the performance of therapeutic proteins, peptides, bi-specifics and full length antibody conjugates

Learn More

PIPELINE

Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on “best in class” biopharmaceutical product opportunities.

Learn More

Partnerships

Partnerships for Next Generation Biologics

Learn More

News

Oct 22, 2019

SAN DIEGO and SHANGHAI, October 22, 2019 /PRNewswire/ -- Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of...

A Convergence of Chemistry And Biology To Create Better Medicine

WHAT WE BELIEVE

Our Technology

PIPELINE

Partnerships

News

Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugates

Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative

Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics